Cite
Breviscapine protects against pathological cardiac hypertrophy by targeting FOXO3a-mitofusin-1 mediated mitochondrial fusion.
MLA
Lin, Xiaobing, et al. “Breviscapine Protects against Pathological Cardiac Hypertrophy by Targeting FOXO3a-Mitofusin-1 Mediated Mitochondrial Fusion.” Free Radical Biology & Medicine, vol. 212, Feb. 2024, pp. 477–92. EBSCOhost, https://doi.org/10.1016/j.freeradbiomed.2024.01.007.
APA
Lin, X., Fei, M.-Z., Huang, A.-X., Yang, L., Zeng, Z.-J., & Gao, W. (2024). Breviscapine protects against pathological cardiac hypertrophy by targeting FOXO3a-mitofusin-1 mediated mitochondrial fusion. Free Radical Biology & Medicine, 212, 477–492. https://doi.org/10.1016/j.freeradbiomed.2024.01.007
Chicago
Lin, Xiaobing, Ming-Zhou Fei, An-Xian Huang, Liu Yang, Ze-Jie Zeng, and Wen Gao. 2024. “Breviscapine Protects against Pathological Cardiac Hypertrophy by Targeting FOXO3a-Mitofusin-1 Mediated Mitochondrial Fusion.” Free Radical Biology & Medicine 212 (February): 477–92. doi:10.1016/j.freeradbiomed.2024.01.007.